NCT01240967View on ClinicalTrials.gov

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Healthy VolunteersPatientsPharmacokineticsRenal Impairment
Interventions
DRUG

TC-5214

Oral tablets, single dose

Trial Locations (2)

Unknown

Research Site, Orlando

Research site, Minneapolis

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY